Loading company…
NeRRe Therapeutics Ltd. is a UK company developing orvepitant, an oral treatment for cough hypersensitivity disorders.
NeRRe Therapeutics Ltd., based in the UK and founded in 2012, is developing orvepitant, a once-daily oral NK-1 receptor antagonist aimed at chronic cough linked to idiopathic pulmonary fibrosis. Its CEO is Mary Kerr and its founder is Mike Trower. The company completed 3 deals, most recently a Series B round of GBP 20.50 million on June 25, 2021, with investors including Advent Life Sciences, Columbus Venture Partners, Forbion, Fountain Healthcare Partners, OrbiMed Advisors and The Future Fund. It reported EBITDA of GBP -7,787,209.50 for 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in